Health
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~ RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:
About this update from Fennec Pharmaceuticals Inc.
[{"type":"image","alt":"Fennec Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Fennec Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":131,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/2efcdbca67a3a46e7d58086ce409299f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tWCaCBwMxCXMcIzvAE80Rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/2efcdbca67a3a46e7d58086ce409299f","width":131,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/tWCaCBwMxCXMcIzvAE80Rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/2efcdbca67a3a46e7d58086ce409299f","width":131,"height":74}},"lazy":false},{"type":"text","content":"~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~","length":176,"tagName":"p"},{"type":"text","content":"~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~","length":227,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program.","length":392,"tagName":"p"},{"type":"text","content":"These four independently led studies build upon the established safety and efficacy of PEDMARK® – currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients – and help to expand understanding of the clinical utility of PEDMARK® in Adolescent and Young Adult (AYA) and adult populations, where significant unmet need remains.","length":511,"tagName":"p"},{"type":"text","content":"“Cisplatin-induced ototoxicity (CIO), or permanent hearing loss related to cispl...